Clinical Trials · NCT07275424
Study of Healthy Aging and Physical Function With Elamipretide
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- David Marcinek
- Enrollment
- 30
- Start date
- Nov 2025
- Locations
- 1 site, United States
- Primary endpoint
- To evaluate the safety and tolerability of daily subcutaneous injections of elamipetide: Number of participants with treatment-related adverse events and Number of participants completed 4 weeks of injection